Studies of the immunological effects of interleukin-2 in patients with bladder cancer and renal cell carcinoma.
Hermann
G G
GG
Dep. of Urology, Herlev hospital.
D002292:Carcinoma, Renal Cell / Q000276:immunology / Q000628:therapy*; D003602:Cytotoxicity, Immunologic; D006801:Humans; D007167:Immunotherapy; D007375:Interleukin-1 / Q000378:metabolism; D007376:Interleukin-2 / Q000627:therapeutic use*; D015850:Interleukin-6 / Q000378:metabolism; D007680:Kidney Neoplasms / Q000276:immunology / Q000628:therapy*; D015979:Killer Cells, Lymphokine-Activated / Q000276:immunology*; D016131:Lymphocyte Subsets / Q000276:immunology; D016246:Lymphocytes, Tumor-Infiltrating / Q000276:immunology; D015375:Receptors, Interleukin-2 / Q000378:metabolism; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism; D001749:Urinary Bladder Neoplasms / Q000276:immunology / Q000628:therapy*
D007375:Interleukin-1; D007376:Interleukin-2; D015850:Interleukin-6; D015375:Receptors, Interleukin-2; D014409:Tumor Necrosis Factor-alpha